These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 34952266)

  • 21. [Phage therapy, an additional strategy against multidrug-resistant bacteria].
    Boniver M; Wotquenne P; Moutschen M; Rousseau AF
    Rev Med Liege; 2022 Sep; 77(9):510-515. PubMed ID: 36082597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phages and their potential to modulate the microbiome and immunity.
    Federici S; Nobs SP; Elinav E
    Cell Mol Immunol; 2021 Apr; 18(4):889-904. PubMed ID: 32901128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolutionary Rationale for Phages as Complements of Antibiotics.
    Torres-Barceló C; Hochberg ME
    Trends Microbiol; 2016 Apr; 24(4):249-256. PubMed ID: 26786863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phage therapy as strategy to face post-antibiotic era: a guide to beginners and experts.
    Royer S; Morais AP; da Fonseca Batistão DW
    Arch Microbiol; 2021 May; 203(4):1271-1279. PubMed ID: 33474609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthetic engineering and biological containment of bacteriophages.
    Mitsunaka S; Yamazaki K; Pramono AK; Ikeuchi M; Kitao T; Ohara N; Kubori T; Nagai H; Ando H
    Proc Natl Acad Sci U S A; 2022 Nov; 119(48):e2206739119. PubMed ID: 36409909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Developing Phage Therapy That Overcomes the Evolution of Bacterial Resistance.
    Oromí-Bosch A; Antani JD; Turner PE
    Annu Rev Virol; 2023 Sep; 10(1):503-524. PubMed ID: 37268007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ameliorating the antimicrobial resistance crisis: phage therapy.
    Saha D; Mukherjee R
    IUBMB Life; 2019 Jul; 71(7):781-790. PubMed ID: 30674079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phage Therapy: The Pharmacology of Antibacterial Viruses.
    Danis-Wlodarczyk K; Dąbrowska K; Abedon ST
    Curr Issues Mol Biol; 2021; 40():81-164. PubMed ID: 32503951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The disparate effects of bacteriophages on antibiotic-resistant bacteria.
    Torres-Barceló C
    Emerg Microbes Infect; 2018 Oct; 7(1):168. PubMed ID: 30302018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical data and safety assessment of phage therapy in humans.
    Nale JY; Clokie MR
    Curr Opin Biotechnol; 2021 Apr; 68():310-317. PubMed ID: 33862490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Virulence-associated factors as targets for phage infection.
    de Melo AG; Morency C; Moineau S
    Curr Opin Microbiol; 2024 Jun; 79():102471. PubMed ID: 38569419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Steering Phages to Combat Bacterial Pathogens.
    Gurney J; Brown SP; Kaltz O; Hochberg ME
    Trends Microbiol; 2020 Feb; 28(2):85-94. PubMed ID: 31744662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens.
    Viertel TM; Ritter K; Horz HP
    J Antimicrob Chemother; 2014 Sep; 69(9):2326-36. PubMed ID: 24872344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Engineering Bacteriophages as Versatile Biologics.
    Kilcher S; Loessner MJ
    Trends Microbiol; 2019 Apr; 27(4):355-367. PubMed ID: 30322741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Approaches to optimize therapeutic bacteriophage and bacteriophage-derived products to combat bacterial infections.
    Reuter M; Kruger DH
    Virus Genes; 2020 Apr; 56(2):136-149. PubMed ID: 32036540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic Engineering and Rebooting of Bacteriophages in L-Form Bacteria.
    Fernbach J; Meile S; Kilcher S; Loessner MJ
    Methods Mol Biol; 2024; 2734():247-259. PubMed ID: 38066374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biofilm control with natural and genetically-modified phages.
    Motlagh AM; Bhattacharjee AS; Goel R
    World J Microbiol Biotechnol; 2016 Apr; 32(4):67. PubMed ID: 26931607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Phage therapy, an alternative to antibiotic therapy?)].
    Reina J; Reina N
    Rev Esp Quimioter; 2018 Apr; 31(2):101-104. PubMed ID: 29451376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Preclinical and Clinical Progress of Bacteriophages and Their Lytic Enzymes: The Parts are Easier than the Whole.
    Abdelkader K; Gerstmans H; Saafan A; Dishisha T; Briers Y
    Viruses; 2019 Jan; 11(2):. PubMed ID: 30678377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancing phage therapy through synthetic biology and genome engineering.
    Lenneman BR; Fernbach J; Loessner MJ; Lu TK; Kilcher S
    Curr Opin Biotechnol; 2021 Apr; 68():151-159. PubMed ID: 33310655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.